London Holds Exhibition to Highlight Scythian Culture

Scythians with horses under a tree. Gold belt plaque. Siberia, 4th–3rd century BC. (The State Hermitage Museum, St Petersburg, 2017)
Scythians with horses under a tree. Gold belt plaque. Siberia, 4th–3rd century BC. (The State Hermitage Museum, St Petersburg, 2017)
TT

London Holds Exhibition to Highlight Scythian Culture

Scythians with horses under a tree. Gold belt plaque. Siberia, 4th–3rd century BC. (The State Hermitage Museum, St Petersburg, 2017)
Scythians with horses under a tree. Gold belt plaque. Siberia, 4th–3rd century BC. (The State Hermitage Museum, St Petersburg, 2017)

The Scythian people, predecessors of the Mongols, ruled a massive area of the Eurasian steppe located between Northern China and the Black Sea, between the ninth and the second century B.C. Little has been known about their culture, until now.

The “Scythians: Warriors of Ancient Siberia” exhibition was launched at the British Museum in London to change the people’s perception of this ancient culture.

Back then, people feared the Scythians, calling them “warriors on horseback”. They used to drink milk from the skulls of their enemies, tattoo themselves with charcoal and consume cannabis.

The Scythians, who spoke Persian, had no written language, so information about them comes from ancient Greeks, Assyrians and Persians.

The exhibition’s website reads: "For centuries, all traces of their culture was missing, and buried under the ice.”

The exhibition, which runs until January 14, wonders whether the civilization is the inspiration behind the famous "Game of Thrones" book and television series.

Most of the 200 pieces featured in the exhibition come from southern Siberia. Many of them are borrowed from the Hermitage Museum in St. Petersburg and are being exhibited outside of Russia for the first time.

The artifacts are are well preserved because they have been buried under ice in the burial hills and tombs of the Altai Mountains in Central Asia.

The exhibit includes pieces discovered at archaeological excavations during the rule of Russia’s Peter the Great in the early 18th century. They include the head of a chief from Scythian tribal, displaying his tattooed skin and glittering gold necklaces. Other pieces include embellished gold for men and women, pendants, leather shoes, and some well-preserved pieces of cheese.

According to the German News Agency (dpa), the exhibit also features engraved stone and massive sarcophagi.

The Scythians, predecessors of the Huns and Mongols, revered horses and relied on them in their wars. Horses, adorned with heavy embellishments, were often buried with their owners to accompany them in their afterlife.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”